SOURCE: The Bedford Report

The Bedford Report

August 24, 2011 08:16 ET

Advanced Cell Technology and Geron Turn to Asia Amidst Heightened US Scrutiny

The Bedford Report Provides Equity Research on Advanced Cell Technology and Geron

NEW YORK, NY--(Marketwire - Aug 24, 2011) - While stem cell financing remains controversial in the United States, North American stem cell research firms have found success forming International partnerships to help boost funding. The Bedford Report examines the outlook for companies in the Biotechnology Industry and provides investment research on Advanced Cell Technology, Inc. (OTCBB: ACTC) and Geron Corporation (NASDAQ: GERN). Access to the full company reports can be found at:

According to Bernard Siegel, founder and full-time executive director of the nonprofit Genetics Policy Institute, US stem cell firms are looking to Asia more for partnerships. According to Siegel there are two fundamental reasons: One is the attractiveness of Asian countries as markets for stem cell treatments. That reflects both high population concentrations as well as willingness by national governments to invest in stem cell research as well as companies commercializing such treatments and encourage additional research by outside parties. The other is Asia's lower regulatory hurdles when compared to the US.

The Bedford Report releases stock research on the Biotechnology Insurance Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at and get exclusive access to our numerous analyst reports and industry newsletters.

Advanced Cell Technology is a biotechnology company applying cellular technology in the field of regenerative medicine. Last year ACTC and CHA Biotech, a leading Korean-based biotechnology company focused on the development of stem cell technologies, announced the formation of a new international joint venture. The new company -- Allied Cell Technology -- will develop human blood cells and other clinical therapies based on ACTC's proprietary hemangioblast cell technology.

Presently, Geron is running clinical trials using embryonic stem cells. Geron is running Phase I trials to see if the cells can restore nerve function in patients who have suffered severe spinal-cord injuries. Three years ago the company granted an exclusive global license to Asia Biotech Corporation for the development of non-prescription dietary food supplements, nutraceuticals and cosmetics containing Geron's small molecule telomerase activating compounds.

The Bedford Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at

Contact Information